股票代码：******

The doctoral team from the Gannan Normal University Drug Screening Research Center visited our company to discuss platform cooperation.

Published:

2022-11-16

On November 4th, Dr. Lu Huiqiang, Dr. Xiao Xiaoping, Dr. Luo Qiang, and Dr. Tian Guiyou from the Gannan Normal University Drug Screening Research Center, a group of four, were invited to visit our company to discuss and inspect talent and project cooperation for our postdoctoral innovation practice base. The company's general manager, Yao Xiaodong, attended.

Dr. Lu and his team first arrived at Comprehensive workshop ， They conducted a detailed visit to the pilot workshop, production workshop, raw material warehouse, finished product warehouse, and other production sites. During the visit, General Manager Yao Xiaodong introduced the workshop's modern production equipment, production process flow, and the construction and usage of the pilot workshop. Both parties also exchanged and discussed the development of new products such as anti-snake venom serum and anti-COVID serum in the pilot workshop.

During the visit, Dr. Lu and his team showed great interest in the scale of our pilot workshop, the advanced level of equipment, and the progress of new product development, observing carefully and asking detailed questions. The doctors unanimously agreed that it is rare for a private enterprise to have such a large-scale pilot workshop and R&D investment, which fully demonstrates our company's high emphasis on research and development work.

(Seminar site)

Then both parties held further discussions and exchanges in the meeting room. At the exchange meeting, General Manager Yao Xiaodong first warmly welcomed the doctors on behalf of the company. Mr. Yao stated that high-level scientific and technological talents are the driving force for enterprise innovation and development, the backbone for promoting economic and social development, and the primary resource for promoting our company's high-quality development. Mr. Yao hopes that through this exchange, both parties can reach a consensus on cooperation, jointly develop, and work together to promote the advancement of the biopharmaceutical industry. Subsequently, Mr. Yao gave the doctor team a detailed introduction to the company's production and operation, subsidiaries, and industrial layout, focusing on the company's biomedicine and industrial platform, R&D laboratories, experimental animal center, ongoing projects, and the operation and postdoctoral entry requirements of our postdoctoral innovation practice base.

Dr. Lu's team also introduced the Gannan Normal University Drug Screening Research Center platform to our company, explaining the platform's current main research areas, the layout of R&D personnel, equipment status, and laboratory business operations. The three accompanying doctors also introduced their own research fields and directions one by one.

After understanding each other's situations, both parties had in-depth communication and exchange on purification processes, affinity chromatography, and organoid technologies. Regarding cooperation matters, Mr. Yao stated that although the two platforms currently differ in research directions, there are still some commonalities in certain research areas, and each platform has its unique advantages. Both parties can fully base cooperation on these characteristics. Dr. Lu highly agreed with Mr. Yao's idea, stating that Jiangsheng has many advantages in projects, equipment, and venues, while the Gannan Normal University Drug Screening Research Center has talent advantages. Both sides will leverage their respective strengths and are willing to jointly tackle some common and key technologies.

Finally, after negotiation, both parties decided to start from postdoctoral entry into the company's postdoctoral innovation practice base, implementing sharing in talent, platform resources, experimental animals, and equipment venues, jointly building the R&D platform, and jointly tackling R&D projects, deepening cooperation, joining forces, and working together tirelessly to accelerate the research and development and implementation of new biopharmaceutical products and technologies!

Focusing on Party members of non-public enterprises in our region to play a leading role

Attending the Grand Event and Sharing Insights -- Party Member Jiang Sheng Watches the Grand Opening of the 20th National Congress of the Communist Party

Add:

Address: No. 198 Huoju Avenue, Jinggangshan Economic & Technological Development Zone, Ji’an, Jiangxi, China

Board Office:

Domestic Sales:

International Sales: